Cohort profile : Finnish Health and Early Life Microbiota (HELMi) longitudinal birth cohort by Korpela, Katri et al.
1Korpela K, et al. BMJ Open 2019;9:e028500. doi:10.1136/bmjopen-2018-028500
Open access 
Cohort profile: Finnish Health and Early 
Life Microbiota (HELMi) longitudinal 
birth cohort
Katri Korpela,1 Evgenia Dikareva,1 Eveliina Hanski,2 Kaija-Leena Kolho,1,3,4 
Willem M de Vos,1,5 Anne Salonen  1
To cite: Korpela K, Dikareva E, 
Hanski E, et al.  Cohort profile: 
Finnish Health and Early Life 
Microbiota (HELMi) longitudinal 
birth cohort. BMJ Open 
2019;9:e028500. doi:10.1136/
bmjopen-2018-028500
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
028500).
ED and EH contributed equally.
Received 11 December 2018
Revised 28 March 2019
Accepted 24 May 2019
1Human Microbiome Research 
Program, Faculty of Medicine, 
University of Helsinki, Helsinki, 
Finland
2Department of Zoology, 
University of Oxford, Oxford, UK
3Children's Hospital, University 
of Helsinki, Helsinki, Finland
4Faculty of Medicine and Health 
Technology, Tampere University, 
Tampere, Finland




Dr Anne Salonen;  
 anne. salonen@ helsinki. fi
Cohort profile
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Purpose HELMi (Health and Early Life Microbiota) is a 
longitudinal, prospective general population birth cohort, 
set up to identify environmental, lifestyle and genetic 
factors that modify the intestinal microbiota development 
in the first years of life and their relation to child health 
and well-being.
Participants The HELMi cohort consists of 1055 
healthy term infants born in 2016–2018 mainly at the 
capital region of Finland and their parents. The intestinal 
microbiota development of the infants is characterised 
based on nine, strategically selected, faecal samples and 
connected to extensive online questionnaire-collected 
metadata at weekly to monthly intervals focusing on the 
diet, other exposures and family’s lifestyle as well as 
the health and growth of the child. Motor and cognitive 
developmental screening takes place at 18 months. 
Infant’s DNA sample, mother’s breast milk sample and 
both parent’s spot faecal samples have been collected.
Findings to date The mean age of the mothers was 32.8 
(SD 4.1) and fathers/coparents 34.8 (5.3) years at the 
time of enrolment. Seventeen percentage (n=180) of the 
infants were born by caesarean section. Just under half 
(49%) were firstborns; 50.7% were males. At 3 months of 
age, 86% of the babies were exclusively breastfed and 2% 
exclusively formula-fed.
Future plans The current follow-up from pregnancy 
to first 24 months will be completed in March 2020, 
totalling to over 10 000 biological samples and over 
50 000 questionnaire entries. The results are expected 
to identify environmental and host factors that affect 
early gut microbiota development and health, and hence 
give indications of how to prevent or reverse microbiota 
perturbations in infancy. This prospective cohort will be 
followed up further to identify how the early microbiota 
relates to later health outcomes, especially weight gain, 
infections and allergic and other chronic diseases.
trial registration number NCT03996304; Pre-results.
IntroduCtIon
During the perinatal period, broadly defined 
as the first 1–2 years after birth, the newborn 
undergoes rapid growth and development 
including that of the immune system.1 In 
parallel, infants are colonised by symbiotic 
gut microbes acquired from the immediate 
environment that are selectively promoted 
by host and environmental factors to reach 
an individual-specific community.2 The early-
life microbiota is now being recognised as 
an important factor for long-term human 
health and development, contributing to 
the Developmental Origins of Health and 
Disease.3 Early microbial stimuli have a 
central role in directing the development of 
the immune system4 5 as well as in metabolic 
programming.6 Rodent experiments indicate 
a presence of relatively narrow postnatal time 
period during which the immune system is 
permissive to microbial instruction,6 7 under-
scoring the importance and durable effects of 
the initial colonisation.
Due to the importance of the early life 
microbiota to lifelong health, several 
prospective birth cohort studies investi-
gating gut microbiota composition in early 
strengths and limitations of this study
 ► Large, prospective microbiota-focused birth cohort: 
frequent intestinal microbiota sampling, parental 
faecal and maternal milk samples and offspring’s 
DNA sample are used to study the individual deter-
minants, rate and patterns of microbiota colonisa-
tion and succession during the first 2 years of life.
 ► Longitudinal metadata collection enables to char-
acterise how early exposure patterns may modify 
the microbiota development and how that relates to 
symptoms and health outcomes in genotype-specif-
ic manner.
 ► Clinical phenotyping during the first 2 years is pri-
marily based on parents’ reports, complemented by 
Bayley Scales test of Infant Development and possi-
bility to extract healthcare and drug purchase data 
from national registries.
 ► Allergic and other immune-mediated diseases are 
modestly over-represented among the parents, pre-
dicting high phenotypic variation among the study 
children already at early age.
 ► Parents from all educational attainment categories 
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life have been undertaken.8–13 However, the Health and 
Early Life Microbiota (HELMi) cohort is the first to 
couple frequent faecal microbiota sampling to exhaus-
tive collection of longitudinal metadata on the lifestyle, 
environmental exposures and health of the infants and 
their family, achieved by interactive web-based question-
naires that parents fill up to weekly intervals throughout 
the extended perinatal period from pregnancy to 2 years 
postpartum.
With the HELMi cohort, we aim to identify novel links 
between the intestinal microbiota development, environ-
mental and genetic factors and health outcomes. In this 
paper, we describe the design of the cohort as well as the 
sample and data collection procedures. Furthermore, we 
present summary characteristics of the infants and their 
parents, focusing on perinatal factors that are known to 
strongly affect early microbiota development.
Cohort desCrIPtIon
study purpose
The HELMi study is a longitudinal cohort designed to 
identify links between the intestinal microbiota devel-
opment, environmental and genetic factors and health 
outcomes. The current establishment of the cohort 
covers follow-up over the first 2 years of life; however, the 
cohort will be followed up as long as possible to assess the 
relation of early microbial and environmental factors to 
infectious and chronic diseases, overweight and obesity 
development as well as cognitive performance.
recruitment
Pregnant women with singleton gestation were recruited 
from the general population mainly in the capital region 
of Finland. Three methods were used to recruit partic-
ipants: (1) displaying recruitment posters and flyers on 
the antenatal clinics within the public healthcare system; 
(2) directly approaching potential participants at the 
antenatal clinics and perinatal ultrasound screens and 
(3) advertising the study on social media. Healthy term 
babies born on gestational weeks 37–42 without known 
congenital defects were included in the study. At least one 
parent in each family had to be Finnish speaking as exten-
sive questionnaires form an integral part of the study.
A total of 1587 families expressed interest in partici-
pating in the HELMi study during the recruitment period 
(February 2016–March 2018). Out of the 1149 consented 
families, 86 families either withdrew from the study before 
the childbirth or were excluded due to preterm birth or 
birth defect (figure 1). Altogether 1063 infants fulfilling 
the inclusion criteria were born, of which 1055 completed 
the data for childbirth details and infant gender. Study 
retention was 96.2% at the age of 3 months. At the time 
of writing, in early March 2019, when the youngest study 
children were 12 months, the retention rate was 91.7% 
(n=967).
data collection
Overview of the HELMi cohort data repository for the 
first 2 year period is provided in figure 2 and described in 
detail below. For each sample type, the currently ongoing 
analyses are indicated.
Biological samples
Stool samples: Nine stool samples from the infants are 
collected at the age of 3, 6, 9, 12 weeks and 6, 9, 12, 18 
and 24 months. In addition, for a subset of 66 infants, 
daily sampling was performed during the 1st, 6th and/or 
12th month as part of a HELMiPlus subproject. Parents 
were asked to provide a spot stool sample around the time 
of childbirth, preferably within 2 weeks of the due date. 
Parents collect the faecal samples at home, freeze them 
immediately at −20°C and transport in a frozen form 
to the laboratory for −80°C storage. Faecal samples are 
processed for the intestinal microbiota analysis using 16S 
rRNA gene amplicon sequencing.
Breast milk sample: Breastfeeding mothers were requested 
to give a breast milk sample at 3 months postpartum at 
the clinic. Mothers gave a milk sample by hand expres-
sion from an uncleaned breast from which they had not 
fed for a minimum of 1 hour. When needed, the nurse 
assisted the expression aseptically. The first 0.5 mL was 
discarded after which a 1 mL sample was collected in a 
chemically clean cup and transferred to freezing phial 
aseptically. Samples were temporarily stored at −20°C 
before transfer to −80°C.
DNA sample: Buccal swabs from the infants were 
collected at 3 months for the extraction of genomic DNA. 
All children are being genotyped for FUT2 gene that 
determines whether mucosal glycans contain terminal 
fucose-sugar residues that are known to mediate inter-
actions between gut microbes and the host, FUT2 repre-
senting the first single gene variant that was associated to 
microbiota composition in humans.14 FUT2 genotyping 
is performed in collaboration with the Finnish Red Cross 
Figure 1 Consort diagram.
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using a previously described single nucleotide polymor-
phism analysis method.14
Questionnaires
We collect a large amount of data on the families’ life-
style, environmental exposures and the health of the 
study infants and their parents using online question-
naires that store the answers instantly on an online data-
base, enabling monitoring and data query already during 
the data collection. After providing basic information on 
the neonate, including the birth date, gender, gestational 
age and birth weight, parents were prompted to fill in 
recurring questionnaires on child’s nutrition, gut func-
tion and care practices weekly for the first 4 months, 
then biweekly until 7 months and finally monthly until 
2 years of child’s age (figure 2). In addition, parents fill 
in comprehensive questionnaires regarding living condi-
tions and infant behaviour and health at 3 month inter-
vals. At child’s age 1 and 2, additional questionnaires 
on diet and motor development are administered. The 
start and end date for illnesses, medication and use of 
Figure 2 Infographic illustrating the type and frequency of biological samples and questionnaires collected in the HELMi 
cohort during the first 2 years. Each horizontal line depicts sample and data collection point in relation to age that is indicated 
on the central bar. The colours refer to the type of sample or data collected, the numbers in the parenthesis to the total number 
of entries per family. ASQ-3, Ages & Stages Questionnaires, Third Edition; BDI-II, Beck Depression Inventory II; BSID-III, Bayley 
Scale of Infant Development III; ECBQ, Early Childhood Behaviour Questionnaire; ITSEA, Infant Toddler Social Emotional 
Assessment; PSI, Parenting Stress Index.
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probiotics and other dietary supplements are reported 
in a continuous manner using a study diary. To promote 
compliance in the questionnaire response rates, parents 
receive automatic reminders via email and text messages.
Nutrition: Breastfeeding and use of infant formula 
are monitored at weekly to monthly frequency, with an 
estimate of percent-based and volume-based share of 
formula in partially breastfed infants before weaning. For 
the first 7 months, parents indicated at weekly to biweekly 
intervals for breastfed infants whether they received 
the milk from the breast or whether it was pumped. We 
record data on timing and type of introduced solid foods 
and monitor which food ingredients are intentionally 
avoided. At child’s age 1 and 2, parents fill food frequency 
questionnaires for the infant and themselves. Families 
that collected daily faecal samples from the infant as part 
of the HELMiPlus subproject also filled a daily food diary 
for the infant.
Growth: Weight and height trajectories are recorded 
based on the 12 measurements taken at child welfare 
clinic during the first 24 months, according to the Finnish 
public health system.
Health and well-being: Infants’ crying, gastrointestinal 
function (based on questions, eg, on regurgitation, stool 
frequency, consistency and colour, signs of stomach ache 
and flatulence) and skin health are monitored with the 
recurring questionnaires. Child’s sleeping habits, onset of 
allergic or other symptoms, need for healthcare services 
and medical diagnoses set by a physician are reported at 
3-month intervals.
Environment and lifestyle: In addition to nutrition, the 
recorded environmental exposures for the study infants 
include person-to-person contacts (number of siblings 
and frequent caregivers; group size, if in day care) and 
environmental factors (housing type, biodiversity, pets, 
travelling, home cleaning practices and hygiene stan-
dards measured based on, eg, on the frequency of vacu-
uming and sterilisation of dummies, if in use).
Maternal and paternal factors: Age, education, smoking 
and alcohol use were recorded for both parents at the 
enrolment; weight and height for body mass index (BMI), 
medical diagnoses and family history of chronic diseases 
were assessed for mothers and biological fathers. For the 
mother, several prenatal and postnatal factors were addi-
tionally assessed, including parity, medication and use 
of probiotics and other supplements during pregnancy 
and lactation, complications of pregnancy and childbirth 
details. Maternal stress during the third trimester was 
determined using a short scaling questionnaire on stress. 
The same questionnaire is administered at 1.5 years post-
partum, together with Beck Depression Inventory II and 
Parenting Stress Index questionnaires.
Developmental, psychological and cognitive assessments
Child’s gross motor skills are assessed with questionnaires 
filled at 1 and 2 years. The fine motor skills as well as 
cognitive and social skills are evaluated at 18 months with 
the following standardised questionnaires: Ages & Stages 
Questionnaires, Third Edition, Infant Toddler Social 
Emotional Assessment and Early Childhood Behaviour 
Questionnaire. In addition, cognitive, fine motor and 
language development is assessed by a psychologist at 
18 months of child’s age using the Bayley Scale of Infant 
Development III for at least 500 infants randomly selected 
from the cohort.
Registry-based data
As previously,15 we will use registry-based antibiotic 
purchase and chronic illness data as exploratory and 
response variables for the microbiota readouts to comple-
ment parents’ self-reported medical information from the 
prenatal and postnatal period. We will exploit the national 
healthcare and drug purchase registries including the 
Finnish Medical Birth Register and the comprehen-
sive Drug Purchase Registry (maintained by the Social 
Insurance Institution, Kela) that provides the history of 
antibiotics and other drugs purchased on prescriptions. 
Current ethical approval covers periods from birth to 2 
years for the child and 5 years preceding the childbirth for 
the mother. Selected chronic conditions, such as atopy, 
inflammatory bowel disease and coeliac disease, entitle 
a person to a special reimbursement of the medication 
when the specified criteria are to be met and approved by 
a physician. Hence, the registry data can be used to verify 
the self-reported physician diagnoses.
Patient and public involvement
Patients and public were not involved in the design or 
conduct of this study. The study participants have been 
offered the opportunity to join a closed Facebook group 
where they can present questions to each other as well as 
to the research team and give feedback about the study. 
Study updates are regularly shared with the participants 
through email newsletters. Additionally, approximately 
once a year, the participants are invited to a webinar, 
where the researchers discuss the study in a broader 
context and answer questions. After filling the recurring 
questionnaires, the parents are provided with instant 
feedback graphics summarising selected answers in 
respect to time and those of the other participant fami-
lies. After completing the 2 year participation, the parents 
can save all the data they provided for their own records. 
After completion of the intestinal microbiota analyses, 
the parents will receive information of the microbiota 
composition of their child.
FIndIngs to dAte
baseline characteristics
At enrolment, 97.3% of the participating families were 
nuclear families with two biological parents, 1.4% hetero-
sexual or homosexual couples where the partner was not 
a biological father of the infant and 1.3% single mothers. 
The basic characteristics of all parents are presented in 
online supplementary table 1. Demographic and anthro-
pometric data were collected only for biological parents 
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(online supplementary table 2). Altogether 88% of the 
study families lived in the capital region, 11.7% in the 
larger metropolitan area and 3.9% elsewhere in Finland. 
The most common housing type was apartment (56%); 
27% of the families lived in semidetached houses and 
17% lived in detached houses with a garden. The mean 
age of the mothers was 32.8 (SD 4.1) and fathers 34.8 
(5.3) years at the time of enrolment. Most parents were 
normal weight; mothers’ mean prepregnancy BMI was 
23.4 (SD 3.7) and fathers’ 25.7 (3.4). Within a family, 
both age and BMI correlated significantly between the 
spouses (figure 3A,B).
The educational attainment of the parents was 
recorded as enrolment statistics. For the HELMi mothers 
(n=1063), the highest level of educational attainment was 
57.6% university, 30.3% university of applied sciences, 
7.3% vocational school, 3.9% upper secondary school 
and 0.9% secondary school. Among the fathers and 
other coparents (n=1063), the maximum level of educa-
tional attainment was 49.5% university, 23.2% univer-
sity of applied sciences, 16.5% vocational school, 7.0% 
upper secondary school and 2.4% secondary school (for 
1.4% data not available). Parents with a degree from an 
academic university or a university of applied sciences 
were over-represented in our cohort (1.7 times higher 
prevalence than in the wider capital region population 
aged 30–34 in 2016). Similarly, parents with no education 
beyond secondary school were under-represented (14.3 
times lower prevalence than in the wider capital region 
population aged 30–34 in 2016).16
Parents’ health
Overall, 57% of the mothers and 45% of the biolog-
ical fathers self-reported at least one medical diagnosis 
(online supplementary table 2) . The most abundant 
diagnosis was ‘allergy’, which was reported by 38% of 
the mothers and 31% of the fathers. Other common 
diagnoses included ‘atopy’ (11% for mothers and 5% for 
fathers), ‘asthma’ (9% and 5%, respectively) and ‘irri-
table bowel syndrome’ (6% and 2%, respectively). The 
prevalence of allergic diseases in the general population 
of Finland is comparable except for the maternal asthma 
which was circa 1.7 times higher in the cohort.17 18 Inflam-
matory bowel disease and coeliac disease were both 
reported by 2% of the mothers and in 2% and 1% of the 
fathers, respectively. The prevalence of diagnosed inflam-
matory bowel disease is 0.9% in the whole Finland19 and 
of coeliac disease 0.7% for women and 0.4% for men 
living in the Southern Finland.20 Hence, these gastroin-
testinal diseases were diagnosed 2.5-fold to 3-fold times 
more frequently among the parents of the cohort than 
in the general population. Pregnancy complications were 
diagnosed in 26% of the mothers. These included gesta-
tional diabetes (19%), hypertension (3%), intrahepatic 
cholestasis of pregnancy (2%), hypothyroidism (1%) 
and pre-eclampsia (1%). The prevalence of gestational 
diabetes in the study population (19%) matches that of 
the general population.21
Infants
The 1055 study infants (51% boys) were born between 
March 2016 and March 2018. The time of gestation 
ranged from 37 to 43 weeks, mean 39.8 weeks (SD 4.4). 
The vast majority (98%) of the babies were born in hospi-
tals and 1% (n=10) at home or in a car. Average birth 
weight was 3558 g and average height was 51 cm. Circa 
half (49%) of the infants were firstborns, 82% were born 
vaginally and 17% via caesarean section (CS), reflecting 
accurately the general rate of CS births in Finland (16.7% 
in 2017).21 The CS births comprised 76 elective, 91 urgent 
and 9 emergency operations (figure 4A; an ‘urgent CS’ 
is a non-scheduled CS without an immediate threat to 
the life of either the mother or fetus, in contrast to an 
‘emergency CS’). In Finland, intrapartum antibiotic 
Figure 3 Parent’s age (A) and BMI (B) distribution and their correlation between the parents within a family. Data are plotted 
on hexagonal bins, which are shaded according to the count of the data points in the aggregate. In addition, histograms of the 
maternal and paternal values are plotted on the top and right, respectively. BMI, body mass index. 
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prophylaxis is administered in all CS deliveries and in 
vaginal deliveries in the case of a positive screening result 
for vaginal Group B Streptococcus (GBS) or other risk 
factors for neonatal GBS disease.22 Among vaginal births, 
25% of the mothers reported prophylactic intrapartum 
antibiotic administration.
Breastfeeding rates at 3 months are presented in 
figure 4B. At 3 months (n=992), 86% of the infants were 
exclusively or almost exclusively breastfed (96%–100% of 
the diet consisting of breast milk) and 2% (n=24) were 
exclusively formula-fed. Based on retrospective reporting 
at 12 months of age (n=910), 86% of the infants had been 
exclusively breastfed (defined as 100% of diet consisting 
of breast milk) for at least the first 3 months. Hence, at 
3 months of age, exclusive breastfeeding was 1.5–2.6 times 
more common in this cohort (86%) than generally in 
Finland,23 24 although the available references date back 
to over a decade and may not reflect the current situation. 
Moreover, our definition for exclusive breastfeeding is 
more liberate than that of the WHO followed by the refer-
ence studies as we did not control for administration of 
water. As many as 70% of the infants were given probiotic 
products by the age of 3 months. Hence, HELMi cohort is 
very well positioned to study the combinatorial effects of 
the known early exposures on the gut microbiota devel-
opment and health and to identify further environment 
and host-related factors that can either potentiate or 
reverse these.
stool samples
By March 2019, ca. 1600 and 7200 stool samples from the 
parents and infants have been collected and returned to 
the university, respectively. The return rate of parental 
faecal sample was 88% (n=927) for the mothers and 63% 
(n=668) for the fathers and other coparents. For the first 
275 families who completed the study protocol by the end 
of 2018, a mean of 8.9 (SD 0.5) out of the nine infant 
faecal samples were received. We are currently in the 
process of carrying out the microbiota analyses using 16S 
RNA gene and internal transcribed spacer (ITS) ampl-
icon sequencing for the total microbiota and species-level 
analysis of bifidobacteria,25 respectively.
Future plans
We are now in the phase of accumulating microbiota 
samples and metadata during the first 2 years of life 
of the study children. For the gut microbiota, analyses 
will be expanded from the compositional analysis to 
shotgun metagenomics to enable strain-level analysis 
for the vertical transfer of the microbiota both from the 
mother and the father as well as functional microbiome 
analysis. Furthermore, we will extend the host genomic 
analysis from single genes to genome-wide analysis, and 
the stool-based analyses from the microbiota to host-de-
rived gut health markers. The breast milk samples will 
be analysed for their human milk oligosaccharides 
content. As part of a separate but highly interlinked 
project, the questionnaire-based environmental expo-
sure analysis will be complemented by collection of 
home dust samples, which will be analysed for bacterial 
16S rRNA gene and fungal ITS amplicon sequencing 
and possibly for quantitative PCR and microbial toxin 
analysis as previously described.26 The dust samples 
are collected once at the child’s age of 1.5–3 years and 
coupled to questionnaire collecting specific data on the 
type of housing, building materials, ventilation system 
and so on.
After this 2-year establishment period, the HELMi 
prospective cohort will continue to collect growth and 
health outcomes, gut microbiota and other biological 
samples as well as data on the main microbiota-affecting 
exposures, such as diet and antibiotics periodically. We 
plan to organise a follow-up every 4–5 years for 15+ years, 
depending on the available funds. The outcomes at focus 
include growth, overweight and obesity development, 
infections, allergic and other chronic diseases as well as 
cognitive performance. Some forthcoming analyses are 
likely to be targeted for specific participant groups (eg, 
antibiotic-exposed or overweight and obese children), 
who could be selected based on the current or latest 
phenotype and their early-life growth or specific expo-
sure that enables focusing on early markers of disease.
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